Genetically engineered mouse models (GEMMs) of cancer are increasingly being used to
assess putative driver mutations identified by large-scale sequencing of human cancer …

Lung cancer is the leading cause of cancer related death, and is divided into two major
histological subtypes, non-small cell lung cancer (NSCLC) and small cell lung cancer …

Lymph nodes are initial sites for cancer metastasis in many solid tumors. However, their role
in cancer progression is still not completely understood. Emerging evidence suggests that …

The extent to which early events shape tumor evolution is largely uncharacterized, even
though a better understanding of these early events may help identify key vulnerabilities in …

Lung cancer is the leading cause of cancer deaths, with small cell lung cancer (SCLC)
representing the most aggressive subtype. Standard treatments have not changed in …

Small cell lung cancer (SCLC) is a recalcitrant neuroendocrine carcinoma with dismal
survival outcomes. A major barrier in the field has been the relative paucity of human tumors …

Recent studies have detailed the genomic landscape of primary endometrial cancers, but
the evolution of these cancers into metastases has not been characterized. We performed …

The development of genetic engineering in the 1970s marked a new frontier in genome-
editing technology. Gene-editing technologies have provided a plethora of benefits to the life …

Cancer patients with lymph node (LN) metastases have a worse prognosis than those
without nodal disease. However, why LN metastases correlate with reduced patient survival …

Genetic evolution that occurs during cancer progression enables tumour heterogeneity,
thereby fostering tumour adaptation, therapeutic resistance and metastatic potential …